Hepatotoxins

Parsons Continues Giant Mine Project With Contract Amendment

Retrieved on: 
Thursday, April 15, 2021

b'CENTREVILLE, Va., April 15, 2021 /PRNewswire/ --Parsons Corporation (NYSE: PSN) announced today that the company\'s contract has been amended by 94 million CAD ($75 million USD) to manage new work at the Giant Mine in the Northwest Territories, Canada.

Key Points: 
  • b'CENTREVILLE, Va., April 15, 2021 /PRNewswire/ --Parsons Corporation (NYSE: PSN) announced today that the company\'s contract has been amended by 94 million CAD ($75 million USD) to manage new work at the Giant Mine in the Northwest Territories, Canada.
  • As part of the amendment, Public Services and Procurement Canada, on behalf of Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC), has extended Parsons\' contract to continue as the Main Construction Manager for remediation efforts of the former gold mine.\n"We are proud to continue leveraging our decades of mine closure and reclamation experience in support of CIRNAC\'s efforts to improve the safety, health and prosperity of the community around Giant Mine," said Jon Moretta, executive vice president, industrial, for Parsons.\nParsons has supported CIRNAC in containing and managing 237 thousand tonnes of arsenic trioxide waste stored underground to protect human and environmental health and safety at Giant Mine since 2017 -- in addition to safely deconstructing the roaster complex from 2013 to 2016.
  • The amended contract will advance elements of the project scope one of the Canadian government\'s largest environmental remediation projects to include freeze pad construction for the highly innovative thermosyphon-based process that will freeze the arsenic trioxide waste in place at the mine, as well as construction of a non-hazardous waste landfill, townsite deconstruction, and underground backfill.\nTo learn more about Parsons\' critical infrastructure expertise, visit Parsons.com/markets/critical-infrastructure/ .\nParsons (NYSE: PSN) is a leading disruptive technology provider in the global defense, intelligence, and critical infrastructure markets, with capabilities across cybersecurity, missile defense, space, connected infrastructure, and smart cities.
  • Please visit parsons.com ,and follow us on LinkedIn and Facebook to learn how we\'re making an impact.\n'

ZetrOZ Systems Partners With the National Institute on Aging

Retrieved on: 
Thursday, April 15, 2021

Pain can be managed by either NSAIDs like aspirin and ibuprofen to powerful narcotics like morphine and codeine.

Key Points: 
  • Pain can be managed by either NSAIDs like aspirin and ibuprofen to powerful narcotics like morphine and codeine.
  • While effective, oral or intravenous administration of these drugs in geriatric patients puts them at higher risk of complications due to possible comorbidities or side effects.
  • The organization also has manufacturing facilities across the United States.
  • ZetrOZ Systems produced UltrOZ, sam Sport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis.

Advisory - One lot of the antidepressant drug APO-Amitriptyline recalled because of nitrosamine impurity

Retrieved on: 
Saturday, April 17, 2021

This means that long-term exposure to a level above what is considered safe may increase the risk of cancer.

Key Points: 
  • This means that long-term exposure to a level above what is considered safe may increase the risk of cancer.
  • NDMA is not expected to cause harm when ingested at at or below the acceptable level.
  • As this recall affects only one lot, patients are not expected to be exposed to levels of NDMA that exceed safe levels for an extended period of time.
  • Should any additional recalls be deemed necessary, Health Canada will update the table below and inform Canadians.\n"

U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive

Retrieved on: 
Friday, April 16, 2021

"\nNearly 10 million American women use short-acting combination contraceptives (estrogen and progestin).

Key Points: 
  • "\nNearly 10 million American women use short-acting combination contraceptives (estrogen and progestin).
  • It has more selective activity in tissues, focusing on those needed to support contraceptive efficacy, cycle control and other beneficial effects of estrogen.
  • According to phase 3 study findings, NEXTSTELLIS demonstrated contraceptive efficacy across all subgroups by age, BMI1 and prior hormonal contraception use.
  • The company has an extensive Women\'s Health portfolio focused on contraceptives, including its flagship birth control product, NEXTSTELLIS.

FDA Releases Action Plan for Reducing Exposure to Toxic Elements from Foods for Babies, Young Children

Retrieved on: 
Thursday, April 8, 2021

Today, we're announcing a new action plan, Closer to Zero , that sets forth our approach to reducing exposure to toxic elements in foods commonly eaten by babies and young children to the lowest possible levels.

Key Points: 
  • Today, we're announcing a new action plan, Closer to Zero , that sets forth our approach to reducing exposure to toxic elements in foods commonly eaten by babies and young children to the lowest possible levels.
  • We recognize that Americans want zero toxic elements in the foods eaten by their babies and young children.
  • While our testing of toxic elements in foods has shown there have already been significant reductions of toxic elements found in foods, the FDA is confident that our new plan will help further advance our work in this area.
  • We plan to combine our efforts to reduce exposure to toxic elements in baby foods with other FDA initiatives to improve the health of mothers, infants, and children.

CytoDyn Providing Leronlimab to a Philippine Hospital for 28 More COVID-19 Patients under Compassionate Special Permit (CSP)

Retrieved on: 
Wednesday, April 7, 2021

Chiral Pharma Corporation, CytoDyns commercial partner in the Philippines, is working closely with the Philippine FDA and the hospital.

Key Points: 
  • Chiral Pharma Corporation, CytoDyns commercial partner in the Philippines, is working closely with the Philippine FDA and the hospital.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • CytoDyn has successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn also completed a Phase 3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.

CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Accelerate Manufacturing of Leronlimab Inventory

Retrieved on: 
Monday, April 5, 2021

The note may be converted at the option of the investor into shares of the Companys common stock at a conversion price of $10.00 per share.

Key Points: 
  • The note may be converted at the option of the investor into shares of the Companys common stock at a conversion price of $10.00 per share.
  • This infusion of capital will help ensure we have sufficient quantities of leronlimab available upon any potential approvals for COVID-19 treatment.
  • The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using leronlimab to treat HIV and metastatic cancer.
  • CytoDyn has successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients.

CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients with the Objective to Duplicate or Surpass 82% Survival Benefit with P-Value of 0.0233 Originally Achieved from Two Weeks of Treatment in CD12 Trial Wi

Retrieved on: 
Thursday, April 1, 2021

These results were achieved with just two doses of leronlimab, one dose at day 0 and a second dose at day 7.

Key Points: 
  • These results were achieved with just two doses of leronlimab, one dose at day 0 and a second dose at day 7.
  • Based on these results, we believe an increased dosage regimen will result in an equal or greater mortality benefit.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • CytoDyn has successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients.

Global Contraceptive Drugs Market (2020 to 2027) - by Product, Age Group, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 1, 2021

The "Contraceptive Drugs Market by Product, Age Group and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Contraceptive Drugs Market by Product, Age Group and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global contraceptive drugs market is segmented into product, age group, end user, and region.
  • The global contraceptive drugs market has been analyzed based on four regions, including North America, Europe, Asia-Pacific, and LAMEA.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global contraceptive drugs market is provided.

FDA Approves Althera's Roszet (rosuvastatin and ezetimibe) Tablets, a New Oral Therapy for Powerful Cholesterol Reduction

Retrieved on: 
Wednesday, March 31, 2021

Roszet contains rosuvastatin, a powerful statin for LDL-C reduction, and ezetimibe, an efficacious cholesterol absorption inhibitor.

Key Points: 
  • Roszet contains rosuvastatin, a powerful statin for LDL-C reduction, and ezetimibe, an efficacious cholesterol absorption inhibitor.
  • Rosuvastatin and ezetimibe have been extensively studied in combination therapy and have been shown to significantly reduce LDL cholesterol beyond the statin alone.
  • Combination therapy has been widely used in hypertension to achieve lower blood pressure targets.
  • Althera is continuing to work with all stakeholders to ensure that Roszet is affordable and accessible to all.